company background image
VBIZ

Viva Biotech Holdings OTCPK:VBIZ.F Stock Report

Last Price

US$0.29

Market Cap

US$369.7m

7D

3.6%

1Y

-73.6%

Updated

17 Sep, 2022

Data

Company Financials +
VBIZ.F fundamental analysis
Snowflake Score
Valuation1/6
Future Growth5/6
Past Performance2/6
Financial Health1/6
Dividends0/6

VBIZ.F Stock Overview

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide.

Viva Biotech Holdings Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Viva Biotech Holdings
Historical stock prices
Current Share PriceHK$0.29
52 Week HighHK$0.85
52 Week LowHK$0.20
Beta0.86
1 Month Change5.46%
3 Month Changen/a
1 Year Change-73.64%
3 Year Changen/a
5 Year Changen/a
Change since IPO-48.67%

Recent News & Updates

Shareholder Returns

VBIZ.FUS Life SciencesUS Market
7D3.6%-6.1%-4.7%
1Y-73.6%-31.3%-18.6%

Return vs Industry: VBIZ.F underperformed the US Life Sciences industry which returned -31.3% over the past year.

Return vs Market: VBIZ.F underperformed the US Market which returned -18.6% over the past year.

Price Volatility

Is VBIZ.F's price volatile compared to industry and market?
VBIZ.F volatility
VBIZ.F Average Weekly Movementn/a
Life Sciences Industry Average Movement10.0%
Market Average Movement7.1%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market2.9%

Stable Share Price: Insufficient data to determine VBIZ.F's volatility over the past 3 months.

Volatility Over Time: Insufficient data to determine VBIZ.F's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
20082,309Chen Cheney Maohttps://www.vivabiotech.com.cn

Viva Biotech Holdings, an investment holding company, provides structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, include protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacokinetics; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody drug research and development services, include antigen preparation, multi-species discovery, monoclonal antibodies, antibodies functional screening and identification, antibody engineering transformation, antibody characteristics, and antibody cell line engineering transformation, as well as offers technology platforms, such as hybridoma, phage and yeast display, mammalian display, VHH antibody technology, high throughput sequencing, computer-aided drug design, HDX-MS, crystal structure determination of protein, and SPR technology. It also provides cell lines, crystal structures, GPCR proteins, antibodies, and proteins.

Viva Biotech Holdings Fundamentals Summary

How do Viva Biotech Holdings's earnings and revenue compare to its market cap?
VBIZ.F fundamental statistics
Market CapUS$369.71m
Earnings (TTM)US$15.92m
Revenue (TTM)US$312.75m

23.2x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VBIZ.F income statement (TTM)
RevenueCN¥2.19b
Cost of RevenueCN¥1.51b
Gross ProfitCN¥679.68m
Other ExpensesCN¥568.35m
EarningsCN¥111.33m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)0.058
Gross Margin31.09%
Net Profit Margin5.09%
Debt/Equity Ratio70.7%

How did VBIZ.F perform over the long term?

See historical performance and comparison